80 FR 24263 - Government-Owned Inventions; Availability for Licensing
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 80, Issue 83 (April 30, 2015)
National Institutes of Health
Federal Register Volume 80, Issue 83 (April 30, 2015)
| Page Range | 24263-24265 | |
| FR Document | 2015-10013 |
[Federal Register Volume 80, Number 83 (Thursday, April 30, 2015)] [Notices] [Pages 24263-24265] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2015-10013] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402- 0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. SUPPLEMENTARY INFORMATION: Technology descriptions follow. A Novel T Cell Therapy Against Patient-Specific Cancer Mutations Description of Technology: This invention is a novel T cell therapy against cancer mutations that are patient specific. Scientists at the National Institutes of Health have developed a method to identify T cells that specifically recognize immunogenic mutations expressed only by cancer cells. Human cancers contain genetic mutations that are unique to each patient. Some of the mutated peptides are immunogenic, can be recognized by T cells, and therefore, may serve as therapeutic targets. The inventors identified cancer-specific mutations from a patient with widely metastatic cholangiocarcinoma by sequencing tumor samples and comparing with normal cells. Using tandem minigene constructs encoding all of the mutations expressed by a patient's tumor, the inventors identified T cells that recognized the immunogenic mutations from the same patient. These mutation-reactive T cells have the potential to eliminate the cancer cells while sparing normal tissues since normal tissues do not express the mutations. The inventors expanded these mutation-reactive T cells in vitro, and infused a highly pure population of these T cells back into the same patient. The patient experienced tumor regression when she was treated with this approach. Potential Commercial ApplicationsPersonalized immunotherapy with mutation-reactive T cells for mediating tumor regression in patients with immunogenic mutations. Mutation-reactive T cell therapy especially beneficial for cancer patients refractory to other therapies. A research tool to identify patient-specific immunogenic mutations in the tumor. Competitive Advantages This patient-specific therapy has the potential application to most epithelial cancers, which account for about 90% of cancer deaths in the United States. Personalized mutation-specific T cells recognize mutations harboring tumor cells only and spare normal tissues. This therapy has no tissue toxicities comparing to traditional chemotherapy and radiotherapy. The infusion of a highly pure population of these mutation-specific T cells may maximize therapy and result in regression of all target lesions. Development Stage Early-stage In vitro data available In vivo data available (human) Ex vivo data available Inventors: Eric Tran, Yong-Chen W. Lu, Paul F. Robbins, Steven A. Rosenberg (all of NCI). Publications 1. Tran E, et al. Cancer immunotherapy based on mutation- specific CD4+ T cells in a patient with epithelial cancer. Science. 2014 May 9; 344(6184):641-5. [PMID 24812403] 2. Robbins P, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013 Jun;19(6):747-52. [PMID 23644516] 3. Tran E, et al. T-cell therapy against cancer mutations. Oncotarget. 2014 Jul 15;5(13):4579-80. [PMID 25046408] Intellectual Property: HHS Reference No. E-229-2014/0--PCT Application No. PCT/US2014/058805 filed October 2, 2014. Related Technology: HHS Reference No. E-233-2014/0--PCT Application No. PCT/US2014/058796 filed October 2, 2014. Licensing Contact: Whitney A. Hastings, Ph.D.; 301-451-7337; [email protected]. Collaborative Research Opportunity: The National Cancer Institute, Surgery Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize T-cell therapy against cancer mutations. For collaboration opportunities, please contact Steven A. Rosenberg, M.D., Ph.D. at [email protected]. A Novel, Personalized T Cell Therapy: T-Cell Receptor Engineered T Cells Targeting Tumor Specific Mutations Description of Technology: This invention is a novel T cell therapy against cancer mutations that are patient specific. Scientists at the National Institutes of Health have developed a method to identify and generate T-cell receptor (TCR) engineered T cells for personalized cancer therapy. The TCR is a complex of integral membrane proteins that recognizes antigens and activates T cells. Human cancers [[Page 24264]] contain genetic mutations that are unique in each patient. The inventors found cancer-specific mutations by sequencing tumors and comparing with normal cells. Using tandem minigene constructs encoding all of the patient's tumor mutations, they first identified T cells that were reactive with the unique mutated antigens expressed only in the patient's tumors. Next, they isolated the mutation-reactive TCRs and engineered peripheral blood T cells from the same patient to express these mutation-reactive TCRs. These personalized TCR engineered T cells can be expanded and infused back into the same patient with the potential to induce tumor regression. Potential Commercial Applications Personalized immunotherapy to treat primary and recurrent epithelial cancer. A research tool to identify patient-specific immunogenic mutations in tumors. A research tool to identify and isolate mutation-specific T cell receptors. Competitive Advantages This patient-specific therapy has the potential application to most epithelial cancers, which account for about 90% of cancer deaths in the United States. Personalized TCR engineered T cells target tumor cells and spare normal tissues. This therapy has no tissue toxicities comparing to traditional chemotherapy and radiotherapy. The infusion of a highly pure population of these T cells expressing mutation-specific TCRs may maximize therapy and result in regression of all target lesions. Development Stage Early-stage In vitro data available Ex vivo data available Inventors: Eric Tran, Yong-Chen W. Lu, Paul F. Robbins, Steven A. Rosenberg (all of NCI). Publications 1. Tran E, et al. Cancer immunotherapy based on mutation- specific CD4+ T cells in a patient with epithelial cancer. Science. 2014 May 9;344 (6184):641-5. [PMID 24812403]. 2. Robbins P, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013 Jun;19(6):747-52. [PMID 23644516]. 3. Tran E, et al. T-cell therapy against cancer mutations. Oncotarget. 2014 Jul 15;5(13):4579-80. [PMID 25046408]. 4. Gros A, et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014 May 1;124(5):2246-59. [PMID 24667641]. Intellectual Property: HHS Reference No. E-233-2014/0--PCT Application No. PCT/US2014/058796 filed October 2, 2014. Related Technology: HHS Reference No. E-229-2014/0--PCT Application No. PCT/US2014/058805 filed October 2, 2014. Licensing Contact: Whitney A. Hastings, Ph.D.; 301-451-7337; [email protected]. Collaborative Research Opportunity: The National Cancer Institute, Surgery Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize TCRs reactive with tumor associated antigens. For collaboration opportunities, please contact Steven A. Rosenberg, M.D., Ph.D. at [email protected]. Recombinant Paramyxoviruses Expressing Optimized Heterologous Antigens Description of Technology: The invention pertains to recombinant paramyxoviruses that express one or more heterologous antigens, such as the human respiratory syncytial virus (RSV) F protein, that have been optimized for increased expression and immunogenicity. The recombinant constructs induce a bivalent immune response to the paramyxovirus vectors and the heterologous antigen. Potential vectors include parainfluenza virus (PIV) serotype 1 and 3, Sendai virus, Newcastle disease virus, PIV2, and PIV5. An exemplary modified heterologous antigen includes the ectodomain of RSV F protein linked to the transmembrane and cytoplasmic domains of the F protein from the PIV vector, which results in efficient incorporation into the vector particle. The RSV F ectodomain can be engineered to be stabilized in an optimal conformation, such as the highly immunogenic prefusion conformation. Additionally, the exemplary heterologous RSV F ectodomain can include one or more amino acid substitutions to modify ectodomain expression, conformation, phenotype, or stability. Potential Commercial Applications RSV vaccine Paramyxovirus vaccines Prophylactic vaccines Competitive Advantages Multi-valence Immunogenicity Development Stage Early-stage In vitro data available Inventors: Peter Collins, Bo Liang Shirin Munir, Anne Schaap-Nutt, Ursula Buchholz, Natalie Mackow, Peter Kwong, Barney Graham, Jason McLellan (all of NIAID). Intellectual Property: HHS Reference No. E-241-2014/0--US Provisional Patent Application 62/105,667 filed January 20, 2015. Related Technologies: HHS Reference No. E-081-2013/0-/5--US Patent Application 14/207,372 filed March 12, 2014; International Patent Application PCT/US2014/026714 filed March 13, 2014. Priority documents as follows: (1) US Provisional Application 61/780,910 filed March 13, 2013; (2) US Provisional Application 61/798,389 filed March 15, 2013; (3) US Provisional Application 61/857,613 filed July 23, 2013; and (4) US Provisional Application 61/863,909 filed August 9, 2013. Licensing Contact: Peter A. Soukas; 301-435-4646; [email protected]. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Jenish Patel at [email protected]. Adaptor for Suspending a Cryovial Over a Centrifuge Tube Description of Technology: The invention pertains to a device and system for expediting the thawing of frozen specimens (e.g., cryopreserved cells) contained in cryo-vials. An adaptor support suspends cryo-vials over a centrifuge tube containing culture medium in an inverted position. The adaptor has an elongated tubular body. While relatively basic, the adaptor dramatically expedites the process of recovering viable cells from frozen specimens. It reduces the labor time for thawing from several minutes to a few seconds. There is virtually no labor involved and enables a single person to load hundreds of samples within minutes. The cells, once thawed, spend essentially no time in liquid cryopreservative, since they are diluted instantly into growth medium contained in the centrifuge tubes. This process ensures the highest viability as well as recovery from each specimen while dramatically increasing throughput. Importantly, the elimination of multiple labor-intensive steps minimizes variation in viability and yield. [[Page 24265]] Potential Commercial Applications Sample preparation Cell culturing Competitive Advantages High throughput Low labor Speed Reduced variability Development Stage: Prototype. Inventors: Mario Roederer, Margaret Beddall, Pratip Chattopadhyay (all of NIAID). Intellectual Property: HHS Reference No. E-080-2015/0--US Patent Application No. 14/661,449 filed March 18, 2015. Licensing Contact: Vince Contreras, Ph.D.; 301-435-4711; [email protected]. Collaborative Research Opportunity: The National Institutes of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Barry Buchbinder at [email protected] or 240-627-3678. Dated: April 24, 2015. Richard U. Rodriguez, Acting Director, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2015-10013 Filed 4-29-15; 8:45 am] BILLING CODE 4140-01-P
![Federal Register / Vol. 80, No. 83 / Thursday, April 30, 2015 / Notices 24263
2015. Time allotted for each U.S. patent applications listed below • Personalized mutation-specific T
presentation may be limited. If the may be obtained by writing to the cells recognize mutations harboring
number of registrants requesting to indicated licensing contact at the Office tumor cells only and spare normal
speak is greater than can be reasonably of Technology Transfer, National tissues. This therapy has no tissue
accommodated during the scheduled Institutes of Health, 6011 Executive toxicities comparing to traditional
open public hearing session, FDA may Boulevard, Suite 325, Rockville, chemotherapy and radiotherapy.
conduct a lottery to determine the Maryland 20852–3804; telephone: 301– • The infusion of a highly pure
speakers for the scheduled open public 496–7057; fax: 301–402–0220. A signed population of these mutation-specific T
hearing session. The contact person will Confidential Disclosure Agreement will cells may maximize therapy and result
notify interested persons regarding their be required to receive copies of the in regression of all target lesions.
request to speak by May 19, 2015. patent applications.
Development Stage
Persons attending FDA’s advisory SUPPLEMENTARY INFORMATION:
committee meetings are advised that the Technology descriptions follow. • Early-stage
Agency is not responsible for providing • In vitro data available
access to electrical outlets. A Novel T Cell Therapy Against • In vivo data available (human)
FDA welcomes the attendance of the Patient-Specific Cancer Mutations • Ex vivo data available
public at its advisory committee Description of Technology: This Inventors: Eric Tran, Yong-Chen W.
meetings and will make every effort to invention is a novel T cell therapy Lu, Paul F. Robbins, Steven A.
accommodate persons with physical against cancer mutations that are patient Rosenberg (all of NCI).
disabilities or special needs. If you specific. Scientists at the National Publications
require special accommodations due to Institutes of Health have developed a
method to identify T cells that 1. Tran E, et al. Cancer immunotherapy
a disability, please contact Philip based on mutation-specific CD4+ T cells in
Bautista at least 7 days in advance of the specifically recognize immunogenic a patient with epithelial cancer. Science.
meeting. mutations expressed only by cancer 2014 May 9; 344(6184):641–5. [PMID
FDA is committed to the orderly cells. Human cancers contain genetic 24812403]
conduct of its advisory committee mutations that are unique to each 2. Robbins P, et al. Mining exomic
meetings. Please visit our Web site at patient. Some of the mutated peptides sequencing data to identify mutated antigens
http://www.fda.gov/Advisory are immunogenic, can be recognized by recognized by adoptively transferred tumor-
Committees/AboutAdvisoryCommittees/ T cells, and therefore, may serve as reactive T cells. Nat Med. 2013
ucm111462.htm for procedures on therapeutic targets. The inventors Jun;19(6):747–52. [PMID 23644516]
public conduct during advisory identified cancer-specific mutations 3. Tran E, et al. T-cell therapy against
cancer mutations. Oncotarget. 2014 Jul
committee meetings. from a patient with widely metastatic 15;5(13):4579–80. [PMID 25046408]
Notice of this meeting is given under cholangiocarcinoma by sequencing
the Federal Advisory Committee Act (5 tumor samples and comparing with Intellectual Property: HHS Reference
U.S.C. app. 2). normal cells. Using tandem minigene No. E–229–2014/0—PCT Application
constructs encoding all of the mutations No. PCT/US2014/058805 filed October
Dated: April 24, 2015.
expressed by a patient’s tumor, the 2, 2014.
Peter Lurie, Related Technology: HHS Reference
inventors identified T cells that
Associate Commissioner for Public Health No. E–233–2014/0—PCT Application
Strategy and Analysis. recognized the immunogenic mutations
from the same patient. These mutation- No. PCT/US2014/058796 filed October
[FR Doc. 2015–10022 Filed 4–29–15; 8:45 am] 2, 2014.
reactive T cells have the potential to
BILLING CODE 4164–01–P
eliminate the cancer cells while sparing Licensing Contact: Whitney A.
normal tissues since normal tissues do Hastings, Ph.D.; 301–451–7337;
not express the mutations. The hastingw@mail.nih.gov.
DEPARTMENT OF HEALTH AND Collaborative Research Opportunity:
HUMAN SERVICES inventors expanded these mutation-
reactive T cells in vitro, and infused a The National Cancer Institute, Surgery
highly pure population of these T cells Branch, is seeking statements of
National Institutes of Health capability or interest from parties
back into the same patient. The patient
Government-Owned Inventions; experienced tumor regression when she interested in collaborative research to
Availability for Licensing was treated with this approach. further develop, evaluate or
commercialize T-cell therapy against
AGENCY: National Institutes of Health, Potential Commercial Applications cancer mutations. For collaboration
HHS. • Personalized immunotherapy with opportunities, please contact Steven A.
ACTION: Notice. mutation-reactive T cells for mediating Rosenberg, M.D., Ph.D. at sar@nih.gov.
tumor regression in patients with A Novel, Personalized T Cell Therapy:
SUMMARY: The inventions listed below
immunogenic mutations. T-Cell Receptor Engineered T Cells
are owned by an agency of the U.S. • Mutation-reactive T cell therapy
Government and are available for Targeting Tumor Specific Mutations
especially beneficial for cancer patients
licensing in the U.S. in accordance with refractory to other therapies. Description of Technology: This
35 U.S.C. 209 and 37 CFR part 404 to • A research tool to identify patient- invention is a novel T cell therapy
achieve expeditious commercialization specific immunogenic mutations in the against cancer mutations that are patient
of results of federally-funded research
mstockstill on DSK4VPTVN1PROD with NOTICES
tumor. specific. Scientists at the National
and development. Foreign patent Institutes of Health have developed a
applications are filed on selected Competitive Advantages method to identify and generate T-cell
inventions to extend market coverage • This patient-specific therapy has receptor (TCR) engineered T cells for
for companies and may also be available the potential application to most personalized cancer therapy. The TCR is
for licensing. epithelial cancers, which account for a complex of integral membrane
FOR FURTHER INFORMATION CONTACT: about 90% of cancer deaths in the proteins that recognizes antigens and
Licensing information and copies of the United States. activates T cells. Human cancers
VerDate Sep<11>2014 17:01 Apr 29, 2015 Jkt 235001 PO 00000 Frm 00034 Fmt 4703 Sfmt 4703 E:\FR\FM\30APN1.SGM 30APN1](https://thefederalregister.org/doc/80_FR_24346/page/1.svg)
![24264 Federal Register / Vol. 80, No. 83 / Thursday, April 30, 2015 / Notices
contain genetic mutations that are infiltrating human tumors. J Clin Invest. 2014 Development Stage
unique in each patient. The inventors May 1;124(5):2246–59. [PMID 24667641].
• Early-stage
found cancer-specific mutations by Intellectual Property: HHS Reference • In vitro data available
sequencing tumors and comparing with No. E–233–2014/0—PCT Application Inventors: Peter Collins, Bo Liang
normal cells. Using tandem minigene No. PCT/US2014/058796 filed October Shirin Munir, Anne Schaap-Nutt,
constructs encoding all of the patient’s 2, 2014. Ursula Buchholz, Natalie Mackow, Peter
tumor mutations, they first identified T Related Technology: HHS Reference Kwong, Barney Graham, Jason McLellan
cells that were reactive with the unique No. E–229–2014/0—PCT Application (all of NIAID).
mutated antigens expressed only in the No. PCT/US2014/058805 filed October Intellectual Property: HHS Reference
patient’s tumors. Next, they isolated the 2, 2014. No. E–241–2014/0—US Provisional
mutation-reactive TCRs and engineered Licensing Contact: Whitney A. Patent Application 62/105,667 filed
peripheral blood T cells from the same Hastings, Ph.D.; 301–451–7337; January 20, 2015.
patient to express these mutation- hastingw@mail.nih.gov. Related Technologies: HHS Reference
reactive TCRs. These personalized TCR Collaborative Research Opportunity: No. E–081–2013/0–/5—US Patent
engineered T cells can be expanded and The National Cancer Institute, Surgery Application 14/207,372 filed March 12,
infused back into the same patient with Branch, is seeking statements of 2014; International Patent Application
the potential to induce tumor capability or interest from parties PCT/US2014/026714 filed March 13,
regression. interested in collaborative research to 2014. Priority documents as follows:
(1) US Provisional Application 61/
Potential Commercial Applications further develop, evaluate or
780,910 filed March 13, 2013;
commercialize TCRs reactive with
• Personalized immunotherapy to (2) US Provisional Application 61/
tumor associated antigens. For 798,389 filed March 15, 2013;
treat primary and recurrent epithelial
collaboration opportunities, please (3) US Provisional Application 61/
cancer.
• A research tool to identify patient- contact Steven A. Rosenberg, M.D., 857,613 filed July 23, 2013; and
specific immunogenic mutations in Ph.D. at sar@nih.gov. (4) US Provisional Application 61/
tumors. Recombinant Paramyxoviruses 863,909 filed August 9, 2013.
• A research tool to identify and Expressing Optimized Heterologous Licensing Contact: Peter A. Soukas;
isolate mutation-specific T cell Antigens 301–435–4646; soukasp@mail.nih.gov.
receptors. Collaborative Research Opportunity:
Description of Technology: The The National Institute of Allergy and
Competitive Advantages invention pertains to recombinant Infectious Diseases is seeking statements
• This patient-specific therapy has paramyxoviruses that express one or of capability or interest from parties
the potential application to most more heterologous antigens, such as the interested in collaborative research to
epithelial cancers, which account for human respiratory syncytial virus (RSV) further develop, evaluate or
about 90% of cancer deaths in the F protein, that have been optimized for commercialize this technology. For
United States. increased expression and collaboration opportunities, please
• Personalized TCR engineered T immunogenicity. The recombinant contact Jenish Patel at jenish.patel@
cells target tumor cells and spare normal constructs induce a bivalent immune nih.gov.
tissues. This therapy has no tissue response to the paramyxovirus vectors
and the heterologous antigen. Potential Adaptor for Suspending a Cryovial
toxicities comparing to traditional
vectors include parainfluenza virus Over a Centrifuge Tube
chemotherapy and radiotherapy.
• The infusion of a highly pure (PIV) serotype 1 and 3, Sendai virus, Description of Technology: The
population of these T cells expressing Newcastle disease virus, PIV2, and invention pertains to a device and
mutation-specific TCRs may maximize PIV5. An exemplary modified system for expediting the thawing of
therapy and result in regression of all heterologous antigen includes the frozen specimens (e.g., cryopreserved
target lesions. ectodomain of RSV F protein linked to cells) contained in cryo-vials. An
the transmembrane and cytoplasmic adaptor support suspends cryo-vials
Development Stage over a centrifuge tube containing culture
domains of the F protein from the PIV
• Early-stage vector, which results in efficient medium in an inverted position. The
• In vitro data available incorporation into the vector particle. adaptor has an elongated tubular body.
• Ex vivo data available The RSV F ectodomain can be While relatively basic, the adaptor
Inventors: Eric Tran, Yong-Chen W. engineered to be stabilized in an dramatically expedites the process of
Lu, Paul F. Robbins, Steven A. optimal conformation, such as the recovering viable cells from frozen
Rosenberg (all of NCI). highly immunogenic prefusion specimens. It reduces the labor time for
Publications conformation. Additionally, the thawing from several minutes to a few
exemplary heterologous RSV F seconds. There is virtually no labor
1. Tran E, et al. Cancer immunotherapy
based on mutation-specific CD4+ T cells in ectodomain can include one or more involved and enables a single person to
a patient with epithelial cancer. Science. amino acid substitutions to modify load hundreds of samples within
2014 May 9;344 (6184):641–5. [PMID ectodomain expression, conformation, minutes. The cells, once thawed, spend
24812403]. phenotype, or stability. essentially no time in liquid
2. Robbins P, et al. Mining exomic cryopreservative, since they are diluted
Potential Commercial Applications
mstockstill on DSK4VPTVN1PROD with NOTICES
sequencing data to identify mutated antigens instantly into growth medium contained
recognized by adoptively transferred tumor- • RSV vaccine in the centrifuge tubes. This process
reactive T cells. Nat Med. 2013 • Paramyxovirus vaccines ensures the highest viability as well as
Jun;19(6):747–52. [PMID 23644516].
3. Tran E, et al. T-cell therapy against
• Prophylactic vaccines recovery from each specimen while
cancer mutations. Oncotarget. 2014 Jul dramatically increasing throughput.
Competitive Advantages
15;5(13):4579–80. [PMID 25046408]. Importantly, the elimination of multiple
4. Gros A, et al. PD–1 identifies the patient- • Multi-valence labor-intensive steps minimizes
specific CD8+ tumor-reactive repertoire • Immunogenicity variation in viability and yield.
VerDate Sep<11>2014 17:01 Apr 29, 2015 Jkt 235001 PO 00000 Frm 00035 Fmt 4703 Sfmt 4703 E:\FR\FM\30APN1.SGM 30APN1](https://thefederalregister.org/doc/80_FR_24346/page/2.svg)
![Federal Register / Vol. 80, No. 83 / Thursday, April 30, 2015 / Notices 24265
Potential Commercial Applications Date: June 23, 2015. Agenda: To review and evaluate contract
Time: 10 a.m. to 3:30 p.m. proposals.
• Sample preparation Agenda: To review and evaluate grant Place: National Institutes of Health,
• Cell culturing applications. Neuroscience Center, 6001 Executive
Competitive Advantages Place: National Institutes of Health, Two Boulevard, Rockville, MD 20852, (Telephone
Democracy Plaza, Suite 920, 6707 Democracy Conference Call).
• High throughput Boulevard, Bethesda, MD 20892. (Virtual Contact Person: Lyle Furr, Scientific
• Low labor Meeting). Review Officer, Office of Extramural Affairs,
• Speed Contact Person: Ruixia Zhou, Ph.D., National Institute on Drug Abuse, NIH,
• Reduced variability Scientific Review Officer, 6707 Democracy DHHS, Room 4227, MSC 9550, 6001
Development Stage: Prototype. Boulevard, Suite 957, Bethesda, MD 20892, Executive Boulevard, Bethesda, MD 20892–
Inventors: Mario Roederer, Margaret 301–496–4773, zhour@mail.nih.gov. 9550, (301) 435–1439, lf33c.nih.gov.
Beddall, Pratip Chattopadhyay (all of Dated: April 24, 2015. (Catalogue of Federal Domestic Assistance
NIAID). David Clary, Program Nos.: 93.279, Drug Abuse and
Intellectual Property: HHS Reference Program Analyst, Office of Federal Advisory Addiction Research Programs, National
No. E–080–2015/0—US Patent Committee Policy. Institutes of Health, HHS)
Application No. 14/661,449 filed March [FR Doc. 2015–10006 Filed 4–29–15; 8:45 am] Dated: April 24, 2015.
18, 2015.
Licensing Contact: Vince Contreras,
BILLING CODE 4140–01–P Michelle Trout,
Ph.D.; 301–435–4711; contrerasv@ Program Analyst, Office of Federal Advisory
mail.nih.gov. Committee Policy.
DEPARTMENT OF HEALTH AND [FR Doc. 2015–10003 Filed 4–29–15; 8:45 am]
Collaborative Research Opportunity: HUMAN SERVICES
The National Institutes of Allergy and BILLING CODE 4140–01–P
Infectious Diseases is seeking statements National Institutes of Health
of capability or interest from parties
interested in collaborative research to National Institute on Drug Abuse; DEPARTMENT OF HEALTH AND
further develop, evaluate or Notice of Closed Meetings HUMAN SERVICES
commercialize this technology. For
Pursuant to section 10(d) of the National Institutes of Health
collaboration opportunities, please
Federal Advisory Committee Act, as
contact Barry Buchbinder at Eunice Kennedy Shriver National
amended (5 U.S.C. App), notice is
BBuchbinder@niaid.nih.gov or 240– Institute of Child Health and Human
hereby given of the following meetings.
627–3678. The meetings will be closed to the Development; Notice of Meeting
Dated: April 24, 2015. public in accordance with the
Richard U. Rodriguez, provisions set forth in sections Pursuant to section 10(d) of the
Acting Director, Office of Technology 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Federal Advisory Committee Act, as
Transfer, National Institutes of Health. as amended. The contract proposals and amended (5 U.S.C. App.), notice is
[FR Doc. 2015–10013 Filed 4–29–15; 8:45 am] the discussions could disclose hereby given of a meeting of the
BILLING CODE 4140–01–P confidential trade secrets or commercial National Advisory Child Health and
property such as patentable material, Human Development Council.
and personal information concerning The meeting will be open to the
DEPARTMENT OF HEALTH AND individuals associated with the contract public as indicated below, with
HUMAN SERVICES proposals, the disclosure of which attendance limited to space available. A
would constitute a clearly unwarranted portion of this meeting will be closed to
National Institutes of Health invasion of personal privacy. the public in accordance with the
Name of Committee: National Institute on provisions set forth in sections
National Institute of Biomedical
Drug Abuse Special Emphasis Panel, Novel 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
Imaging and Bioengineering; Notice of
Treatment for Drug-Induced Respiratory as amended for the review and
Closed Meeting Depression (2239). discussion of grant applications.
Pursuant to section 10(d) of the Date: May 12, 2015. Individuals who plan to attend and
Federal Advisory Committee Act, as Time: 10 a.m. to 12 p.m. need special assistance, such as sign
Agenda: To review and evaluate contract
amended (5 U.S.C. App.), notice is language interpretation or other
proposals.
hereby given of the following meeting. Place: National Institutes of Health, reasonable accommodations, should
The meeting will be closed to the Neuroscience Center, 6001 Executive notify the contact person listed below in
public in accordance with the Boulevard, Rockville, MD 20852, (Telephone advance of the meeting.
provisions set forth in sections Conference Call). Name of Committee: National Advisory
552b(c)(4) and 552b(c)(6), title 5 U.S.C., Contact Person: Lyle Furr, Scientific Child Health and Human Development
as amended. The grant applications and Review Officer, Office of Extramural Affairs, Council.
the discussions could disclose National Institute on Drug Abuse, NIH, Date: June 4, 2015.
confidential trade secrets or commercial DHHS, Room 4227, MSC 9550, 6001 Open: June 4, 2015, 8:00 a.m. to 12:10 p.m.
property such as patentable material, Executive Boulevard, Bethesda, MD 20892– Agenda: Report of the Director, NICHD;
9550, (301) 435–1439, lf33c.nih.gov. Report of the Acting Director, Division of
and personal information concerning
This notice is being published less than 15 Extramural Research, NICHD; Division of
mstockstill on DSK4VPTVN1PROD with NOTICES
individuals associated with the grant
days prior to the meeting due to the timing Intramural Research, NICHD DIR
applications, the disclosure of which limitations imposed by the review and Reorganization and Discussion; NIH BRAIN
would constitute a clearly unwarranted funding cycle. Initiative Update and New Business of the
invasion of personal privacy. Name of Committee: National Institute on Council.
Name of Committee: National Institute of Drug Abuse Special Emphasis Panel, NIDA Closed: June 4, 2015, 1:00 p.m. to
Biomedical Imaging and Bioengineering Blending Initiative (2244). Adjournment.
Special Emphasis Panel, NIBIB 2015–10 U01 Date: June 4, 2015. Agenda: To review and evaluate grant
Quantum Review. Time: 10 a.m. to 12 p.m. applications.
VerDate Sep<11>2014 17:01 Apr 29, 2015 Jkt 235001 PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 E:\FR\FM\30APN1.SGM 30APN1](https://thefederalregister.org/doc/80_FR_24346/page/3.svg)
Document Created: 2018-02-21 10:14:39
Document Modified: 2018-02-21 10:14:39
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Contact | Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402- 0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. | |
| FR Citation | 80 FR 24263 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR